The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions.

People born with inherited high cholesterol — known as the “evil cousin” — may soon have access to new and potentially ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

There was a time when whisky was considered medicine. The spirit was used as an antiseptic on battlefields, and was sold in ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart ...